Biotechnology

With a new CFO known for billion-dollar deals and a promising gout drug, Crystalys Therapeutics is gearing up for a pivotal run at the global market.

After a $16.5M funding round, the smart-shipping innovator hires a top finance exec to scale its attack on the $35B problem of spoiled medicine.

A new, self-administered RNA therapy for hereditary angioedema gains EU approval, promising fewer attacks and greater freedom for thousands of patients.

With a $150M+ capital raise and a top cancer immunologist on board, the T1D Fund is making a strategic play to shift from managing T1D to curing it.

With $35.1M in new funding, Infinitopes is launching a human trial for its AI-designed vaccine aimed at preventing oesophageal cancer recurrence.

BioAge Labs is developing an oral drug for diabetic macular edema, a breakthrough that could end the need for frequent, invasive eye injections for millions.

A new partnership between Vida Health and RxSaveCard offers employers a way to subsidize pricey weight-loss drugs outside of traditional insurance plans.

A new AI-driven platform from CAS aims to democratize complex IP research, making high-stakes patent analysis accessible to entire organizations.

The global CRO is acquiring specialized firm Catalyst Clinical Research, aiming to dominate the booming oncology trial market. But can it navigate the risks?

The newly launched Cord Blood Council tackles financial and operational hurdles to strengthen a vital life-saving resource for transplants and future therapies.

Novavax lands a major partnership with Pfizer for its Matrix-M adjuvant, a deal that provides a crucial financial boost and validates its pivot to a tech provider.

Ascletis Pharma unveils ASC37, a next-gen, once-monthly obesity drug claiming superior potency and convenience, challenging giants like Eli Lilly.

GSK's subsidiary Tesaro inks a deal worth up to $285M with Alteogen to create an under-the-skin version of its cancer drug Jemperli.

A Tokyo clinic and the Nobel Sustainability Trust are championing a radical new paradigm. Is this the future of health or a controversial rebrand?

Amidst policy shifts, AIESEC US champions the J-1 program, connecting firms with skilled global talent to drive innovation and cultural exchange.

With booming exports and robust government backing, Italy is making a strategic play to become a global life sciences powerhouse. Here's what's driving the momentum.

A novel cell therapy for Parkinson's earns a key FDA designation, signaling a potential paradigm shift from managing symptoms to reversing the disease.

Australian biopharma Immuron reports strong global sales for its travel supplement and launches a new IBS product, navigating industry mergers and digital trends.

Veteran drug discoverer Dr. Adam Davenport joins as CSO, bringing expertise in cutting-edge modalities to accelerate client pipelines in a competitive market.

At a major San Francisco summit, Chinese biotechs unveiled breakthrough heart and cancer drugs, signaling a strategic shift from manufacturing to global innovation.